Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects will receive multiple ascending doses of G1090N up to 1200mg twice daily for 7 consecutive days.”In the company’s words, NCT07110441 on ClinicalTrials.gov
- Tested for
- Acute-on-Chronic Liver Failure
- Main trialPhase 1
- “A Phase 1, Open-Label Study to Assess Pharmacokinetics, Safety and Tolerability of G1090N in Healthy Subjects”In the company’s words, NCT07110441 on ClinicalTrials.gov
Other drugs for Acute-on-Chronic Liver Failure
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 1 Dec 2025 | Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026